Related Experiment Video
Updated: Sep 22, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease]
M Sánchez-Chapado1, J Angulo Cuesta, M Guil Cid
1Servicio de Urología, Hospital Principe de Asturias, Facultad de Medicina, Universidad de Alcalá de Henares, Madrid.
Objectives:
The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.
Methods:
Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.
Results:
Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.
Conclusions:
Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.
Related Concept Videos
Lysosomal Hydrolases
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Alterations in Muscle Tone lll

